ArticleHepatology communications2020
Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities.
Article in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.Hepatology international · 2024Pooled it
- Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis.Endocrine · 2024Pooled it
- Effects of Telemedicine on Obese Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Association of Vascular Endothelial Growth Factor A +936 C/T Polymorphism With Non-Alcoholic Fatty Liver Disease in a Bangladeshi Population: A Case-Control Study.Health science reports · 2026Article
- Emerging insights into PPARActa pharmaceutica Sinica. B · 2026Review
- Predictive modeling and clinical decision tools for risk stratification in steatotic liver disease.Clinical and molecular hepatology · 2026Review
- The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.Liver cancer · 2026Review
- Insights into Metabolically Healthy Obesity-A Narrative Review.Journal of clinical medicine · 2026Review
- Review
- Prediabetic cardiomyopathy is attenuated by hypothalamic PVN oxytocin neuron activation.The Journal of physiology · 2026Article
- Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current cardiology reports · 2026Review
- The liver-muscle axis in metabolic dysfunction-associated steatotic liver disease: a narrative review and conceptual framework for body-composition phenotyping.Frontiers in medicine · 2026Review
- Eating behaviors and liver health in metabolic dysfunction-associated fatty liver disease: the serial mediating roles of Mediterranean diet adherence and adiposity.Frontiers in nutrition · 2026Article
- Association between body composition and metabolic dysfunction-associated steatotic liver disease in Chinese general population: a cross-sectional study stratified by sex and obesity status.Frontiers in public health · 2026Article
- Higher diet quality is associated with a lower prevalence of MASLD and adverse health outcomes: insights from NHANES 2005 to 2020.European journal of nutrition · 2025Article
- Clinical and Genetic Predictors of Non-Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- From gut to liver: Exploring the relationship between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.BMC gastroenterology · 2025Article
- Elevated Cholinesterase Activity and the Metabolic Syndrome-Dissecting Fatty Liver, Insulin Resistance and Dysglycaemia.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although nonalcoholic fatty liver disease (NAFLD) is associated with obesity, it can also occur in lean and metabolically normal individuals. Our aim was to determine the effect of different combinations of abdominal adiposity and overall adiposity on the mortality of NAFLD. The Third National Health and Nutrition Examination Survey with mortality data from the National Death Index were used. NAFLD was defined as steatosis without other liver diseases. Body composition was categorized according to waist circumference (WC) and body mass index (BMI). Obesity pattern was defined according to BMI (lean, overweight, and obese) and WC (normal and obese) using accepted definitions. The "metabolically abnormal" group had visceral obesity, insulin resistance, type 2 diabetes, hypertension, or hyperlipidemia. Of the 9,341 study individuals (47.9% male; 76.8% white), NAFLD was present in 3,140 (33.6%), of whom 0.6% had lean BMI and normal WC, and 1.7% had lean BMI and obese WC. The prevalence of metabolically normal NAFLD was 3.26% (95% confidence interval [CI]: 2.62%-3.90%), with most of these subjects having lean BMI (79.2%). During an average follow-up of 22.4 years, 24.1% of the subjects died from all causes. Among these deceased individuals, 41.7% had NAFLD at baseline. Causes of death were cardiovascular disease (24.8%), cancer-related (24.3%), type 2 diabetes-related (4.4%), and liver-related (1.7%). Individuals with NAFLD who were lean by BMI but obese by WC had higher risk of all-cause mortality. Individuals with NAFLD with normal BMI but obese WC had a higher risk of cardiovascular mortality (hazard ratio 2.63 [95% CI: 1.15-6.01]) as compared with overweight (by BMI) NAFLD with normal WC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.